Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F. Tzogani K, et al. Among authors: pieters r. Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23. Oncologist. 2015. PMID: 25616431 Free PMC article. Review.
New approach methodologies to enhance human health risk assessment of immunotoxic properties of chemicals - a PARC (Partnership for the Assessment of Risk from Chemicals) project.
Snapkow I, Smith NM, Arnesdotter E, Beekmann K, Blanc EB, Braeuning A, Corsini E, Sollner Dolenc M, Duivenvoorde LPM, Sundstøl Eriksen G, Franko N, Galbiati V, Gostner JM, Grova N, Gutleb AC, Hargitai R, Janssen AWF, Krapf SA, Lindeman B, Lumniczky K, Maddalon A, Mollerup S, Parráková L, Pierzchalski A, Pieters RHH, Silva MJ, Solhaug A, Staal YCM, Straumfors A, Szatmári T, Turner JD, Vandebriel RJ, Zenclussen AC, Barouki R. Snapkow I, et al. Among authors: pieters rhh. Front Toxicol. 2024 Apr 9;6:1339104. doi: 10.3389/ftox.2024.1339104. eCollection 2024. Front Toxicol. 2024. PMID: 38654939 Free PMC article. Review.
Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.
Brigitha LJ, Mondelaers V, Liu Y, Albertsen BK, Zalewska-Szewczyk B, Rizzari C, Kotecha RS, Pieters R, Huitema ADR, van der Sluis IM. Brigitha LJ, et al. Among authors: pieters r. Pharm Res. 2024 Apr;41(4):711-720. doi: 10.1007/s11095-024-03693-3. Epub 2024 Mar 27. Pharm Res. 2024. PMID: 38538970
BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.
Alieva M, Barrera Román M, de Blank S, Petcu D, Zeeman AL, Dautzenberg NMM, Cornel AM, van de Ven C, Pieters R, den Boer ML, Nierkens S, Calkoen FGJ, Clevers H, Kuball J, Sebestyén Z, Wehrens EJ, Dekkers JF, Rios AC. Alieva M, et al. Among authors: pieters r. Nat Protoc. 2024 Mar 19. doi: 10.1038/s41596-024-00972-6. Online ahead of print. Nat Protoc. 2024. PMID: 38504137 Review.
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, Bierings M, van den Bos C, de Haas V, Hoogerbrugge PM, Tissing WJE, Veening MA, Pieters R. van der Sluis IM, et al. Among authors: pieters r. J Clin Oncol. 2024 Feb 2:JCO2301797. doi: 10.1200/JCO.23.01797. Online ahead of print. J Clin Oncol. 2024. PMID: 38306592
994 results